-
-
-
-
-
-
-
Regeneron Completes Acquisition of Decibel Therapeutics, Adding Promising Gene Therapy Programs for Hearing Loss
-
-
-
-
-
-
-
Regeneron (REGN) and Intellia (NTLA) Report Initial Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001
-
-
-
-
-
-
-
Regeneron Strengthens Commitment to Oncology through Purchase of Sanofi's Stake in the Regeneron and Sanofi Collaboration on Libtayo® (cemiplimab), a PD-1 Inhibitor Approved for Multiple Forms of Can
-
-
-
-
-
-
-
BMO Capital Reiterates Outperform Rating, $780 Price Target on Regeneron Pharma (REGN) Following Checkmate (CMPI) Acquisition
-
-
-
-
-
-
-
After-Hours Stock Movers 08/05: (GRPN) (CSOD) (CVNA) Higher; (DRNA) (ZNGA) (NVAX) Lower (more...)
-
-
-
-
-
-
-
U.S. signs agreement with AstraZeneca to develop, supply COVID-19 antibody treatment
-
-
-
-
-
-
-
FDA Approves Dupixent® (dupilumab) for Chronic Rhinosinusitis with Nasal Polyposis
-
924,087 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All